BASELGA JOSE ET AL: "Novel anticancer targets: revisiting ERBB2 and discovering ERBB3", NATURE REVIEWS. CANCER, NATUR PUBLISHING GROUP, LONDON, GB, vol. 9, no. 7, 1 July 2009 (2009-07-01), pages 463-475, XP009139034, ISSN: 1474-175X, DOI: 10.1038/NRC2656 (B1)

HARRIS LYNDSAY N ET AL: "Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342", BREAST CANCER RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 8, no. 6, 27 November 2006 (2006-11-27), page R66, XP021027012, ISSN: 1465-5411, DOI: 10.1186/BCR1622 (B1)

LEE-HOEFLICH SI TUEN ET AL: "A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 68, no. 14, 1 July 2008 (2008-07-01), pages 5878-5887, XP009145458, ISSN: 0008-5472 (B1)

WO-A2-2010/019952 (B1)

NIE LIN ET AL: "Efficacy of MM121 in ER+ and triple negative breast cancer studies", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 51, 17 April 2010 (2010-04-17), page 436, XP001537417, ISSN: 0197-016X (B1)

SCHNEIDER B P ET AL: "Triple-negative breast cancer: Risk factors to potential targets", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 14, no. 24, 15 December 2008 (2008-12-15), pages 8010-8018, XP002580460, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-08-1208 (B1)

SCHOEBERL BIRGIT ET AL: "An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation", CANCER RESEARCH, AACR, PHILADELPHIA, PA, vol. 70, no. 6, 9 March 2010 (2010-03-09), pages 2485-2494, XP002581703, ISSN: 1538-7445, DOI: 10.1158/0008-5472.CAN-09-3145 [retrieved on 2010-03-09] (B1)

M. R. CAMPBELL ET AL: "HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy", CLINICAL CANCER RESEARCH, vol. 16, no. 5, 1 March 2010 (2010-03-01), pages 1373-1383, XP55007713, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-09-1218 (B1)